Market Overview
The Global Acute Ischemic Stroke (AIS) Market is estimated at USD 8,517.0 Million in 2023 and is projected to reach USD 11,185.3 Million by 2030, growing at a CAGR of 4.0% over the forecast period (2023-2030).
Acute ischemic stroke (AIS) occurs when blood flow in a cerebral artery is blocked by a clot, which is a thickened mass of blood. Clots are classified as either thrombotic or embolic depending on where they form in the body. The most common type of stroke is a thrombotic stroke, which occurs when a clot forms in an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from another part of the body, such as the heart, and travels through the bloodstream before lodging in a narrower vessel of the brain. Large vessel occlusion (LVO) is responsible for nearly half of all acute ischemic strokes. OVL is the most serious and debilitating type of stroke because the clot blocks large arteries and prevents blood flow to vital parts of the brain.
Increasing prevalence of ischemic stroke globally is expected to drive the growth of the global acute ischemic stroke (AIS) market.
For example, according to the 2023 Heart Disease and Stroke Statistical Update factsheet provided by the American Heart Association, the global prevalence of stroke in 2019 was 101.5 million people. , while that of ischemic stroke was 77.2 million. Overall, the age-standardized stroke prevalence rate in 2019 was highest in Oceania, Southeast Asia, North Africa and the Middle East, as well as East Asia. East. Countries in parts of North Africa and the Middle East, southern Sub-Saharan Africa, high-income countries in North America and Southeast Asia had the highest stroke prevalence rate highest ischemic. Additionally, in 2019, there were 6.6 million deaths worldwide due to cerebrovascular diseases. In 2019, a total of 3.3 million people worldwide died from ischemic stroke, 2.9 million died from intracerebral hemorrhage, and 0.4 million died from subarachnoid hemorrhage.
Post-COVID Impact
The COVID-19 pandemic has had a profound impact on various sectors, including healthcare. The Acute Ischemic Stroke (AIS) market, responsible for addressing the needs of patients suffering from this condition, has also experienced notable changes. This article explores the post-COVID impact on the AIS market, including the challenges faced and the potential opportunities that lie ahead.
COVID-19's Influence on AIS Care
- Disruption of stroke services and delayed or postponed diagnoses
- Impact of overwhelmed healthcare systems on AIS patient management
- Increased risk of stroke due to COVID-19 infection and related complications
Shifting Treatment Landscape
- Modified treatment protocols to minimize COVID-19 exposure
- Utilization of telemedicine and remote monitoring for initial assessments and follow-ups
- Adoption of advanced technologies to streamline AIS diagnosis and treatment
Market Dynamics and Challenges
- Market size and revenue projections considering the pandemic's effects
The Crohn's disease market faces several restraints. Firstly, the etiology of Crohn's disease is not fully understood, making it challenging to develop targeted therapies. Secondly, the high cost of treatment, including biologics and surgical interventions, can limit access to care for some patients. Thirdly, the potential side effects and risks associated with existing treatments pose concerns for patients and may impact treatment adherence. Additionally, the unpredictable nature of the disease and the occurrence of flare-ups make it difficult to achieve long-term remission. Lastly, regulatory hurdles and the lengthy and costly drug approval process can impede the introduction of new therapies into the market.
Considering the effects of the pandemic, the Crohn's disease market experienced disruptions due to healthcare resource reallocation, reduced patient visits, and delayed elective procedures. However, as the healthcare system gradually recovers, the market is expected to regain momentum. While the pandemic introduced short-term uncertainties, the increasing prevalence of Crohn's disease and ongoing research efforts are expected to drive market growth. The market size and revenue projections post-pandemic will largely depend on the successful development and commercialization of novel therapies, advancements in personalized medicine, and improved access to care for patients.
- Delays in clinical trials for new AIS therapies
In addition to the mentioned restraints, the Crohn's disease market has also been impacted by delays in clinical trials for new therapies, including anti-inflammatory drugs. The COVID-19 pandemic has disrupted many clinical trial activities, leading to a slowdown in the development and evaluation of potential treatments. These delays further hinder the introduction of innovative therapies into the market, prolonging the time it takes for patients to access new and potentially more effective treatment options for Crohn's disease.
- Supply chain disruptions affecting the availability of medical devices and medications
Supply chain disruptions have significantly affected the availability of medical devices and medications in the Crohn's disease market. The COVID-19 pandemic disrupted global supply chains, causing delays and shortages in the production, distribution, and transportation of essential medical supplies. This includes medications, such as biologics and other specialized drugs, as well as medical devices used for diagnostic and therapeutic purposes. These disruptions have posed challenges for patients and healthcare providers, leading to potential treatment interruptions, difficulty in accessing necessary medications, and increased costs. The industry is working to address these issues and restore a stable supply chain to ensure the availability of vital resources for Crohn's disease management.
Emerging Opportunities
- Rise in demand for stroke care facilities and specialized centers
There has been a significant rise in demand for stroke care facilities and specialized centers. This is driven by the increasing incidence of strokes and the recognition of the importance of timely and specialized care. These facilities provide comprehensive stroke treatments, including thrombectomy, rehabilitation services, and stroke prevention programs, to improve patient outcomes and reduce long-term disability. The establishment of dedicated stroke centers helps streamline care, enhance coordination among healthcare providers, and deliver specialized interventions tailored to the unique needs of stroke patients.
- Focus on developing telestroke programs to enhance access to care
In response to the rising demand for stroke care, healthcare systems are focusing on developing telestroke programs. These programs leverage telemedicine technologies to provide remote consultations, assessments, and treatment recommendations for stroke patients. Telestroke programs enhance access to specialized stroke care, particularly in underserved areas, improve response times, and facilitate timely interventions, ultimately leading to better patient outcomes and reduced disability. The use of telestroke programs also helps alleviate the burden on stroke centers by providing efficient triage and optimizing resource utilization.
- Advancements in AI and machine learning for early stroke detection and prediction
Advancements in AI and machine learning have revolutionized early stroke detection and prediction. These technologies analyze patient data, such as medical imaging and electronic health records, to identify patterns and markers that indicate the risk of stroke. AI algorithms can rapidly analyze large datasets, aiding in the early identification of stroke symptoms, improving diagnostic accuracy, and enabling timely interventions. Machine learning models also contribute to predicting stroke outcomes, assisting healthcare providers in making informed decisions regarding treatment strategies and preventive measures. These advancements have the potential to enhance stroke care by enabling early interventions and improving patient outcomes.
Government Initiatives and Regulations
- Increased funding for stroke research and treatment
There has been an increased focus on funding for stroke research and treatment. Recognizing the significant burden of stroke on healthcare systems and patients, governments, organizations, and philanthropic entities are allocating resources to support research initiatives, clinical trials, and the development of innovative therapies and interventions. This increased funding aims to improve our understanding of stroke, advance treatment options, enhance rehabilitation programs, and ultimately reduce the impact of stroke on individuals and society.
- Implementation of policies to improve stroke care delivery
Governments and healthcare authorities are implementing policies to improve stroke care delivery. These policies focus on various aspects, such as establishing stroke systems of care, promoting stroke prevention and education programs, ensuring timely access to stroke treatments, and enhancing rehabilitation services. These efforts aim to optimize stroke care delivery, reduce disparities in access and outcomes, and improve the overall quality of stroke care provided to patients.
- Regulatory changes to expedite approval processes for essential AIS therapies
Regulatory bodies are implementing changes to expedite the approval processes for essential acute ischemic stroke (AIS) therapies. These changes include accelerated review pathways, streamlined regulatory requirements, and priority review designations. By reducing the time required for regulatory approval, these changes aim to facilitate timely access to critical AIS therapies, ultimately improving patient outcomes and reducing disability.
Future Outlook
- Recovery and rebound of the AIS market post-pandemic
The AIS market is expected to experience a recovery and rebound post-pandemic. As healthcare systems stabilize and regain momentum, the demand for acute ischemic stroke treatments is anticipated to increase. Factors such as the resumption of elective procedures, the implementation of telestroke programs, and advancements in stroke care are likely to contribute to the growth of the AIS market, leading to improved patient outcomes and a positive market outlook.
- Acceleration of innovative research and development activities
The COVID-19 pandemic has led to the acceleration of innovative research and development activities in the AIS market. The urgency to address healthcare challenges has fostered collaborations and investments in novel technologies, therapies, and treatment approaches. This rapid pace of innovation is expected to bring about significant advancements in AIS care, leading to improved outcomes and patient experiences.
- Integration of digital health solutions and telemedicine in stroke care delivery
The integration of digital health solutions and telemedicine in stroke care delivery has gained significant momentum. These technologies enable remote consultations, real-time monitoring, and access to expert stroke care, facilitating timely interventions and reducing treatment delays. The use of digital platforms and telemedicine enhances accessibility, improves patient outcomes, and optimizes resource utilization in stroke care delivery.
Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic.
In the context of the coronavirus (COVID-19) global pandemic caused by SARS-CoV-2, a possible link between this disease and stroke has been proposed. Between March 24, 2020 and July 17, 2020, PCR-confirmed COVID-19 patients with ischemic stroke were admitted to an academic health system in metropolitan Atlanta, Georgia (U.S.). 13 (2.5%) of 396 ischemic stroke patients admitted during this study period were also diagnosed with COVID-19. Each of the 13 patients had at least one stroke-related co-morbidity. The most common type of ischemic stroke was embolic, with four cases explained by atrial fibrillation. During the study period, COVID-19 patients had a significantly higher rate of cryptogenic stroke than non-COVID-19 patients.
Market: Restraint
High cost of treatment and lack of transparent reimbursement policies is expected to restrain the market growth over the forecast period. For instance, according to an article published by National Center for Biotechnology Information (NCBI), published in August 2018, the average in-hospital cost per acute stroke patient was approximately US$ 6961 ± 15,663 in Lebanon. Cost determinants were length of hospital stay, length of intensive care unit stay, stroke type, stroke severity, modified Rankin scale, third-party payers, operations, and infectious complications.
Market Segmentation
By Therapeutics: The AIS market can be segmented based on therapeutics into thrombolytics, antiplatelet agents, anticoagulants, neuroprotective agents, and other supportive therapies. Thrombolytics, such as tissue plasminogen activators (tPAs), are commonly used for restoring blood flow in AIS patients. Antiplatelet agents and anticoagulants help prevent further clot formation, while neuroprotective agents aim to protect brain cells from damage during stroke.
By Distribution Channel: The distribution channel segmentation of the AIS market includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are a crucial distribution channel due to the immediate need for acute stroke treatments and emergency care. Retail pharmacies provide accessibility for patients to obtain prescribed medications post-hospitalization. Online pharmacies offer convenience and home delivery options for AIS medications.
Geographical Analysis:
North America: The AIS market in North America holds a significant share due to the high prevalence of stroke, well-established healthcare infrastructure, and advanced treatment options. The presence of key market players and ongoing research activities contribute to the growth of this region. The region also benefits from supportive government initiatives and reimbursement policies for stroke care.
Latin America: The AIS market in Latin America is growing, driven by increasing awareness, improving healthcare infrastructure, and rising investment in stroke care. However, challenges such as limited access to advanced therapies and healthcare disparities across the region may impact market growth.
Asia Pacific: The AIS market in Asia Pacific is expected to witness substantial growth due to the high burden of stroke in countries like China and India. Rapid urbanization, increasing healthcare expenditure, and improving access to healthcare services are driving market expansion. However, the availability of stroke care facilities and awareness among the population remain areas of focus.
Middle East and Africa: The AIS market in the Middle East and Africa is growing steadily, with increasing efforts to enhance stroke care infrastructure and services. The market is driven by rising awareness, improving healthcare systems, and investments in stroke care facilities. However, economic and healthcare disparities across the region present challenges to market growth.
Key Players
Major players operating in the global acute ischemic stroke (AIS) market include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc.